Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 241-620-3 | CAS number: 17636-10-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 12.342 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 308.55 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- A NOAEL of 350 mg/kg bw /day from a chronic oral repeated dose toxicity study with the read across substance CAS 19767-45-4 is available (Toolbox-Prediction, Chemservice S.A., 2012). This value was converted into the corrected inhalatory NOAEC taking into account the standard respiratory factor of 1/0.38 m3/kg/d and the absorption rates for Absorption (dermal 50 %, worst case - inhalation 100 %) and the standard respiratory volume in humans/ worker respiratory volume (6.7 m3 (8 h) / 10 m3 (8 h)).
- AF for dose response relationship:
- 1
- Justification:
- default
- AF for differences in duration of exposure:
- 1
- Justification:
- since it is a chronic study
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- No allometric scalling should be applied in case of oral-to-inhalation extrapolation
- AF for other interspecies differences:
- 2.5
- Justification:
- default; no substance and route specific information on toxicokinetic and toxicodynamic is available for animals and humans
- AF for intraspecies differences:
- 5
- Justification:
- default for workers
- AF for the quality of the whole database:
- 1
- Justification:
- default
- AF for remaining uncertainties:
- 2
- Justification:
- remaining uncertainties due to use of read across
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 3.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 350 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Long-term systemic DNEL for the dermal route has been derived from the NOAEL of 350 mg/kg bw established in the oral chronic study in rats with mesna - CAS 19767-45-4 (Chemservice S.A., 2012). As seen in the acute dermal study in rats, the substance was not systemically toxic by the dermal route and is also expected to be of lower systemic toxicity after prolonged exposure with the skin. The starting point for the DNEL derivation can be obtained by conversion of oral NOAEL into dermal NOAEL (route-to-route extrapolation).
- AF for dose response relationship:
- 1
- Justification:
- default
- AF for differences in duration of exposure:
- 1
- Justification:
- since it is a chronic study
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- default factor for rats
- AF for other interspecies differences:
- 2.5
- Justification:
- default; no substance and route specific information on toxicokinetic and toxicodynamic is available for animals and humans
- AF for intraspecies differences:
- 5
- Justification:
- default for workers
- AF for the quality of the whole database:
- 1
- Justification:
- default
- AF for remaining uncertainties:
- 2
- Justification:
- remaining uncertainties due to use of read across
Acute/short term exposure
- Hazard assessment conclusion:
- no DNEL required: short term exposure controlled by conditions for long-term
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no DNEL required: short term exposure controlled by conditions for long-term
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
The calculation of the DNELs is performed in accordance with the principles given in ECHA (2012) “Guidance of Information Requirements and Chemical Safety Assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health.”.
Available dose descriptors:
For 1-Propanesulfonic acid, 3-mercapto-, monosodium salt, DNELs are needed for chronic exposure by the oral (only for consumers), dermal (for workers and consumers) and inhalation routes of exposure (workers and consumers). Inhalation is not a relevant route of exposure due to the low vapour pressure of the substance. Since 1-Propanesulfonic acid, 3-mercapto-, monosodium salt does not represent an acute hazard (not classified for acute toxicity), no DNELS for acute systemic toxicity need to be derived.
No DNELs are needed for local effects because there is no dose-response and route-specific information on these endpoints. Long-term systemic DNELs cover sufficiently local effects.
From all available data for the different human health endpoints it is clear that 1-Propanesulfonic acid, 3-mercapto-, monosodium salt exerts its effect by a threshold mode of action. Thus, DNELs can be calculated for the different threshold endpoints based on the most relevant dose descriptors per endpoint. DNELs are derived based on the available toxicity data for the related substances, reflecting the routes, duration and frequency of exposure. DNELs are derived for workers and the general population. The general population includes consumers and humans exposed via the environment.
There are following annotations for each endpoint:
- Since the substance is not acutely toxic by the dermal route of exposure, no acute DNEL needs to be derived. This is based on a LD50 greater than 2000 mg/kg bw (as evident from all weight of evidence pieces).
- Acute DNELs for inhalation (systemic and local) are not necessary since there is no acute toxic hazard by inhalation.
- A qualitative approach in hazard assessment for eye and skin irritation/corrosion and skin sensitisation is used because no dose descriptors are available on these endpoints.
- For the non-threshold endpoints (mutagenicity and carcinogenicity) no DNELs can be derived because a No-Effect Level could not be established from the relevant studies. Hence, the hazard characterization is based on a qualitative approach.
- There is no animal data on repeated oral, dermal or inhalation exposure. To cover this endpoint, data from an oral gavage chronic study in rats with the read across substance mesna - CAS 19767-45-4 (Toolbox-Prediction, Chemservice S.A. 2012) has been used to calculate the long-term DNELs.
-No DNELs for reprotoxic effects are derived because the Toolbox-Predictions indicate no reproductive hazard arising from analogue substances of 1 -Propanesulfonic acid, 3 -mercapto-, monosodium salt. Therefore the substance is not expected to be reprotoxic and the hazard is covered sufficiently by the systemic long-term DNELs.
First of all, available dose descriptors were converted into a corrected starting point to take into account differences in routes of exposure between experimental animals and humans and differences in human and animal exposure conditions. Consecutively, the assessment factors have been applied to the correct starting point to obtain the endpoint specific DNELs. Assessment factors (AFs) correct uncertainties and variability within and between species in the effect data.
The assessment factors are applied in accordance with the recent ECHA guidance document and the ECETOC Technical Report No. 110, October 2010.
Modification of the relevant dose descriptors to the correct starting point:
Bioavailability (absorption)
50% of dermal absorption is considered for the target substance. The dermal absorption in rats and in humans is assumed to be the same since no experimentally determined values for dermal absorption of the target chemical in rats and in humans are available. In case of oral to inhalation extrapolation, 50% absorption is assumed for oral absorption in rats and 100% absorption for inhalation is assumed in humans (worst case; according to the ECETOC Report No 110, 100% absorption for inhalation can be used in case of absence of substance specific data for absorption).
Route-to-route extrapolation:
Oral-to-inhalation extrapolation is performed to assess long-term inhalation effects in humans. In addition, oral-to-dermal extrapolations are conducted to assess long-term dermal effects in humans.
Exposure conditions:
Exposure time differed in workers and in the chronic oral study in rat with the read across substance mesna (CAS 19767-45-4). Rats were exposed to the test substance once daily via gavage, while workers are exposed 8h daily (5days/week). No modification of the starting points for exposure conditions was necessary since the systemic dose after oral administration of the test material was already assessed in respiratory volume taken for rats during 8 hours (0.38m³) (see formula of modification of the starting point by oral-to-inhalation extrapolation.
Respiratory volumes:
Differences in the respiratory volumes between experimental animals and humans were used when an oral rat NOAEL from the chronic gavage study in rats with mesna (CAS 19767 -45 -4) was used to assess inhalation exposure in humans. 0.38 m³/kg/day is the standard respiratory volumes in rats during 8h exposure. 6.7 and 10 m³ are standard respiratory volumes for workers under normal conditions and by light activity, respectively.
Applying of assessment factors:
Interspecies differences:
The species-specific default assessment factor of 4 for allometric scaling for rats is applied in case of usage of oral NOAEL to derive dermal DNEL.
No allometric scaling factor is applied in case of oral-to-inhalation extrapolation.
An additional assessment factor of 2.5 is applied for remaining interspecies differences in toxicodynamics between rats and humans.
Intraspecies differences:
Assessment factor of 5 is applied for workers for all endpoints and for all exposure routes. The factor of 10 is used in the process of DNEL-calculation for general population.
Extrapolation of duration:
An assessment factor of 1 was applied in case of the chronic oral repeated dose toxicity study with mesna (CAS 19767-45-4) as no extrapolation is needed.
Quality of whole data base:
An assessment factor for uncertainties in the quality of the data base is regarded to be 1, as all studies used to derive the DNELs were GLP-guideline studies..
Issues related to dose response:
Assessment factor of 1 was used.
Remaining uncertainties:
As the DNELs are based on a study performed with the read across substance mesna (CAS: 19767-45-4), an additional assessment factor of 2 was used for the remaining uncertainties.
Calculation of endpoint-specific DNELs for workers
Long-term exposure - systemic effects (dermal)
The oral NOAEL of 350 mg/kg bw was converted into the dermal NOAEL: Dermal NOAEL = oral NOAEL x (ABS oral-rat/ABS dermal-human) = 350 mg/kg bw x (50%/50%) = 350 mg/kg bw.
DNEL = 350 mg/kg bw/(4 x 2.5 x 5 x 1 x 1 x 1 x 2) = 3.5 mg/kg bw. Assessment factors are: 4 – interspecies, 2.5 – remaining interspecies differences, 5 – intraspecies, 1 – study duration (chronic study), 1 – dose response (clear dose response), 1 – quality of data base (default), 2 - remaining uncertainties (due to read-across).
Long-term exposure - systemic effects (inhalation)
The oral NOAEL of 350 mg/kg bw was converted into the inhalation NOAEC:
Inhalation NOAEC = oral NOAEL x (1/sRVrat) x (ABS oral-rat/ ABS inhal-human) x (6.7 m³/10 m³) = 350 mg/kg bw x (1/0.38 m³/kg/day) x (50%/100%) x (6.7/10) = 308.55 mg/m³
DNEL = 308.55 mg/m³/(2.5 x 5 x 1 x 1 x 1 x 2) = 12.342 mg/m³. Assessment factors are: 2.5 – remaining interspecies differences, 5 – intraspecies, 1 – study duration (chronic study), 1 – dose response (clear dose response), 1 – quality of data base (default) 2 - remaining uncertainties (due to read across).
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 3.04 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 152.174 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- A NOAEL of 350 mg/kg bw /day from a chronic oral repeated dose toxicity study with the read across substance CAS 19767-45-4 is available (Toolbox-Prediction, Chemservice S.A., 2012). This value was converted into the corrected inhalatory NOAEC taking into account the standard respiratory volume of rats of 1/1.15 m3/kg/d and the absorption rates for Absorption (dermal 50 %, worst case - inhalation 100 %).
- AF for dose response relationship:
- 1
- Justification:
- default
- AF for differences in duration of exposure:
- 1
- Justification:
- since it is a chronic study
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- No allometric scalling should be applied in case of oral-to-inhalation extrapolation
- AF for other interspecies differences:
- 2.5
- Justification:
- default; no substance and route specific information on toxicokinetic and toxicodynamic is available for animals and humans
- AF for intraspecies differences:
- 10
- Justification:
- default for consumers
- AF for the quality of the whole database:
- 1
- Justification:
- default
- AF for remaining uncertainties:
- 2
- Justification:
- remaining uncertainties due to use of read across
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.75 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 350 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Long-term systemic DNEL for dermal route has been derived from the NOAEL of 350 mg/kg bw established in the oral chronic study in rats with mesna - CAS 19767-45-4 (Chemservice S.A., 2012). As seen in the acute dermal study in rats, the substance was not systemically toxic by the dermal route and is also expected to be of lower systemic toxicity after prolonged exposure with the skin. The starting point for the DNEL derivation can be obtained by conversion of oral NOAEL into dermal NOAEL (route-to-route extrapolation).
- AF for dose response relationship:
- 1
- Justification:
- default
- AF for differences in duration of exposure:
- 1
- Justification:
- since it is a chronic study
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- default factor for rats
- AF for other interspecies differences:
- 2.5
- Justification:
- default; no substance and route specific information on toxicokinetic and toxicodynamic is available for animals and humans
- AF for intraspecies differences:
- 10
- Justification:
- default for consumers
- AF for the quality of the whole database:
- 1
- Justification:
- default
- AF for remaining uncertainties:
- 2
- Justification:
- remaining uncertainties due to use of read across
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.75 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 350 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Long-term systemic DNEL for oral route has been derived from the NOAEL of 350 mg/kg bw established in the oral chronic study in rats with mesna - CAS 19767-45-4 (Chemservice S.A., 2012).
- AF for dose response relationship:
- 1
- Justification:
- default
- AF for differences in duration of exposure:
- 1
- Justification:
- since it is a chronic study
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- default for rats
- AF for other interspecies differences:
- 2.5
- Justification:
- default; no substance and route specific information on toxicokinetic and toxicodynamic is available for animals and humans
- AF for intraspecies differences:
- 10
- Justification:
- default for consumers
- AF for the quality of the whole database:
- 1
- Justification:
- default
- AF for remaining uncertainties:
- 2
- Justification:
- remaining uncertainties due to use of read across
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
The principles of the DNEL calculation for the general population are the same as already described for workers. However, there are additional considerations or deviations for:
Modification of the starting point:
Bioavailability (absorption)
The oral absorption in rats and in humans is assumed to be the same since no information for oral absorption for the target chemical in rats and in humans is available. Oral absorption in animals and in humans is considered to be the same.
Respiratory volumes:
- No differences in the respiratory volumes under normal conditions and by light activity in humans were taken into account.
Applying of assessment factors:
- A higher assessment factor of 10 (in place of 5 for workers) for intraspecies variation/differences of human population was used.
Calculation of endpoint-specific DNEL for general population
Long-term exposure - systemic effects (oral)
The oral NOAEL of 350 mg/kg bw was not modified for differences in absorption by oral route since no substance- and route specific information is available.
DNEL = 350 mg/kg bw/(4 x 2.5 x 10 x 1 x 1 x 1 x 2) = 1.75 mg/kg bw. Assessment factors are: 4 – interspecies, 2.5 – remaining interspecies differences, 10 – intraspecies, 1 – study duration (chronic study), 1 – dose response (clear dose response), 1 – quality of data base (default), 2 - remaining uncertainties (due to read-across).
Long-term exposure - systemic effects (dermal)
The oral NOAEL of 350 mg/kg bw was converted into the dermal NOAEL: Dermal NOAEL = oral NOAEL x (ABS oral-rat/ABS dermal-human) = 350 mg/kg bw x (50/50%) = 350 mg/kg bw.
DNEL = 350 mg/kg bw/(4 x 2.5 x 10 x 1 x 1 x 1 x 2) = 1.75 mg/kg bw. Assessment factors are: 4 – interspecies, 2.5 – remaining interspecies differences, 10 – intraspecies, 1 – study duration (chronic study), 1 – dose response (clear dose response), 1 – quality of data base (default), 2 - remaining uncertainties (due to read across).
Long-term exposure - systemic effects (inhalation)
The oral NOAEL of 350 mg/kg bw was converted into the inhalation NOAEC:
Corrected inhalation NOAEC = oral rat NOAEL x (1/1.15 m³/kg bw/day) x (ABS oral-rat/ABS inhal-human), where 1.15 is standard respiratory volume (m³/kg bw) of rats during 24 h exposure, ABS is absorption (values are the same as described for workers).
Corrected Inhalation NOAEC = 350 mg/kg bw x (1/1.15 m³/kg/day) x (50%/100%) = 152.174 mg/m³
DNEL = 152.174 mg/m³/(2.5 x 10 x 1 x 1 x 1 x 2) = 3,04 mg/m³. Assessment factors are: 2.5 – remaining interspecies differences, 10 – intraspecies, 1 – study duration (chronic study), 1 – dose response (clear dose response), 1 – quality of data base (default), 2 - remaining uncertainties (due to read-across).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.